secwatch.observer — SEC 8-K summary
======================================

Issuer:     Annovis Bio, Inc. (ANVS)
CIK:        0001477845
Form:       8-K
Filed at:   2025-02-05T23:59:59+00:00
Accession:  0001104659-25-009279
Event type: other_material
Sentiment:  negative
Materiality: 0.70
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Annovis Bio closes $21M public offering of 5.25M units with warrants at $4.00/unit
--------------------------------------------------------------------------------

- Offering of 5,250,000 units (1 share + 1 warrant) at $4.00 per unit; gross proceeds $21M.
- Warrants exercisable at $5.00 per share, immediately exercisable, 5-year term.
- Net proceeds to fund Phase 3 study of Buntanetap for Alzheimer's disease and working capital.
- Offering closed on February 4, 2025; underwritten by ThinkEquity LLC.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1477845/000110465925009279/0001104659-25-009279-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1477845/000110465925009279/tm255497d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-009279

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer